Progression-Free Survival as a Predictor of Overall Survival in Metastatic Renal Cell Carcinoma Treated With Contemporary Targeted Therapy

BACKGROUND: The majority of metastatic renal cell carcinoma (mRCC) clinical trials that examined targeted agents used progression-free survival (PFS) as the primary endpoint. Whether PFS can be used as a predictor of overall survival (OS) is unknown. METHODS: Patients from 12 cancer centers who rece...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Heng, Daniel Y. C., Xie, Wanling, Bjarnason, Georg A., Vaishampayan, Ulka, Tan, Min-Han, Knox, Jennifer, Donskov, Frede, Wood, Lori, Kollmannsberger, Christian, Rini, Brian I., Choueiri, Toni K.
Format: Artigo
Langue:Inglês
Publié: 2010
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3856357/
https://ncbi.nlm.nih.gov/pubmed/21656741
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.25750
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires